CD1530

CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases) [1][2][3][4][5][6].

Product Specifications

CAS Number

[107430-66-0]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Bacterial; MMP; RAR/RXR; Reactive Oxygen Species (ROS) ; TGF-beta/Smad; β-catenin

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt; TGF-beta/Smad; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Infection; Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/cd1530.html

Purity

98.01

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(C2=CC=C3C=C(O)C(C4(C5)CC6CC5CC(C6)C4)=CC3=C2)C=C1

Molecular Formula

C27H26O3

Molecular Weight

398.49

Precautions

H315, H319, H335

References & Citations

[1]Shimono K, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011 Apr;17 (4) :454-60.|[2]Murholm M, et al. Retinoic acid has different effects on UCP1 expression in mouse and human adipocytes. BMC Cell Biol. 2013 Sep 23;14:41.|[3]Tang XH, et al. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci U S A. 2014 Jun 17;111 (24) :8907-12.|[4]Yimiti D, et al. CD1530, selective RARγ agonist, facilitates Achilles tendon healing by modulating the healing environment including less chondrification in a mouse model. J Orthop Res. 2025 Feb;43 (2) :273-284.|[5]Kim W, et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018 Apr 5;556 (7699) :103-107.|[6]Shirasawa H, et al. Retinoic Acid Receptor Agonists Suppress Muscle Fatty Infiltration in Mice. Am J Sports Med. 2021 Feb;49 (2) :332-339.